Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560750372> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W2560750372 endingPage "241" @default.
- W2560750372 startingPage "241" @default.
- W2560750372 abstract "241 Background: There is currently no standard second-line chemotherapy for platinum- refractory UC. Both paclitaxel and docetaxel are commonly used but response rates are < 20% and no survival advantage has been shown. In this multi-institutional phase II study, we evaluated the efficacy and tolerability of a new albumin-bound nanoparticle formulation of paclitaxel, known as Abraxane (ABI-007) as a single agent in patients with platinum-refractory metastatic UC. Methods: Patients with measurable UC, progressing on or after first-line platinum-based chemotherapy were enrolled onto this two-stage trial. ABI-007 was given at 260 mg/m 2 IV q3weekly until progression. Clinical evaluation, CBC and blood chemistries were performed every cycle with restaging CT scans every 2 cycles. Results: Accrual is now complete with 48 patients enrolled. Baseline characteristics: Male: Female 40:8; median age 68; ECOG Performance Status 0:1:2, 15:24:8. 248 cycles were delivered: median 5.5 cycles/pt with 17/48 pts (35%) requiring dose reductions. Most frequent adverse events (AE) were alopecia (12%), fatigue (12%), pain (12%), neuropathy (9%) and nausea (4%). The most frequent grade 3+ AE were pain (45%), hypertension (14%), fatigue (8%), joint stiffness (5%), neuropathy (4%) and weakness (4%). Forty patients are evaluable for response: 1 (2.5%) complete response (CR), 11 (28%) partial responses (PR), 9 (23%) stable disease (SD) and 20 (49%) progressive disease. One patient was inevaluable for response, 7 patients are too early for evaluation. Conclusions: Single-agent ABI-007 was well tolerated with a response rate (CR+PR) of 33% (12/36) and a clinical benefit rate (CR+PR+SD) of 58% (21/36), representing one of the highest reported response rates to date in the second-line UC setting. These results suggest further study of ABI-007 in urothelial carcinoma is warranted. No significant financial relationships to disclose." @default.
- W2560750372 created "2016-12-16" @default.
- W2560750372 creator A5017887586 @default.
- W2560750372 creator A5042123586 @default.
- W2560750372 creator A5044972820 @default.
- W2560750372 creator A5052896359 @default.
- W2560750372 creator A5058331275 @default.
- W2560750372 creator A5065891328 @default.
- W2560750372 creator A5067610911 @default.
- W2560750372 creator A5076126577 @default.
- W2560750372 creator A5079441446 @default.
- W2560750372 date "2011-03-01" @default.
- W2560750372 modified "2023-10-16" @default.
- W2560750372 title "Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma (UC)." @default.
- W2560750372 doi "https://doi.org/10.1200/jco.2011.29.7_suppl.241" @default.
- W2560750372 hasPublicationYear "2011" @default.
- W2560750372 type Work @default.
- W2560750372 sameAs 2560750372 @default.
- W2560750372 citedByCount "11" @default.
- W2560750372 countsByYear W25607503722012 @default.
- W2560750372 countsByYear W25607503722013 @default.
- W2560750372 countsByYear W25607503722019 @default.
- W2560750372 crossrefType "journal-article" @default.
- W2560750372 hasAuthorship W2560750372A5017887586 @default.
- W2560750372 hasAuthorship W2560750372A5042123586 @default.
- W2560750372 hasAuthorship W2560750372A5044972820 @default.
- W2560750372 hasAuthorship W2560750372A5052896359 @default.
- W2560750372 hasAuthorship W2560750372A5058331275 @default.
- W2560750372 hasAuthorship W2560750372A5065891328 @default.
- W2560750372 hasAuthorship W2560750372A5067610911 @default.
- W2560750372 hasAuthorship W2560750372A5076126577 @default.
- W2560750372 hasAuthorship W2560750372A5079441446 @default.
- W2560750372 hasConcept C121332964 @default.
- W2560750372 hasConcept C121608353 @default.
- W2560750372 hasConcept C126322002 @default.
- W2560750372 hasConcept C141071460 @default.
- W2560750372 hasConcept C142424586 @default.
- W2560750372 hasConcept C143998085 @default.
- W2560750372 hasConcept C197934379 @default.
- W2560750372 hasConcept C2776694085 @default.
- W2560750372 hasConcept C2776907518 @default.
- W2560750372 hasConcept C2777292972 @default.
- W2560750372 hasConcept C2778375690 @default.
- W2560750372 hasConcept C2778822529 @default.
- W2560750372 hasConcept C2779984678 @default.
- W2560750372 hasConcept C2780352672 @default.
- W2560750372 hasConcept C2780580376 @default.
- W2560750372 hasConcept C2781190966 @default.
- W2560750372 hasConcept C2911057145 @default.
- W2560750372 hasConcept C3019882237 @default.
- W2560750372 hasConcept C31760486 @default.
- W2560750372 hasConcept C71924100 @default.
- W2560750372 hasConcept C87355193 @default.
- W2560750372 hasConcept C90924648 @default.
- W2560750372 hasConceptScore W2560750372C121332964 @default.
- W2560750372 hasConceptScore W2560750372C121608353 @default.
- W2560750372 hasConceptScore W2560750372C126322002 @default.
- W2560750372 hasConceptScore W2560750372C141071460 @default.
- W2560750372 hasConceptScore W2560750372C142424586 @default.
- W2560750372 hasConceptScore W2560750372C143998085 @default.
- W2560750372 hasConceptScore W2560750372C197934379 @default.
- W2560750372 hasConceptScore W2560750372C2776694085 @default.
- W2560750372 hasConceptScore W2560750372C2776907518 @default.
- W2560750372 hasConceptScore W2560750372C2777292972 @default.
- W2560750372 hasConceptScore W2560750372C2778375690 @default.
- W2560750372 hasConceptScore W2560750372C2778822529 @default.
- W2560750372 hasConceptScore W2560750372C2779984678 @default.
- W2560750372 hasConceptScore W2560750372C2780352672 @default.
- W2560750372 hasConceptScore W2560750372C2780580376 @default.
- W2560750372 hasConceptScore W2560750372C2781190966 @default.
- W2560750372 hasConceptScore W2560750372C2911057145 @default.
- W2560750372 hasConceptScore W2560750372C3019882237 @default.
- W2560750372 hasConceptScore W2560750372C31760486 @default.
- W2560750372 hasConceptScore W2560750372C71924100 @default.
- W2560750372 hasConceptScore W2560750372C87355193 @default.
- W2560750372 hasConceptScore W2560750372C90924648 @default.
- W2560750372 hasIssue "7_suppl" @default.
- W2560750372 hasLocation W25607503721 @default.
- W2560750372 hasOpenAccess W2560750372 @default.
- W2560750372 hasPrimaryLocation W25607503721 @default.
- W2560750372 hasRelatedWork W2038406412 @default.
- W2560750372 hasRelatedWork W2103201965 @default.
- W2560750372 hasRelatedWork W2138054646 @default.
- W2560750372 hasRelatedWork W2162934203 @default.
- W2560750372 hasRelatedWork W2261580129 @default.
- W2560750372 hasRelatedWork W2327170850 @default.
- W2560750372 hasRelatedWork W2999060407 @default.
- W2560750372 hasRelatedWork W3197516152 @default.
- W2560750372 hasRelatedWork W4246966695 @default.
- W2560750372 hasRelatedWork W4283772908 @default.
- W2560750372 hasVolume "29" @default.
- W2560750372 isParatext "false" @default.
- W2560750372 isRetracted "false" @default.
- W2560750372 magId "2560750372" @default.
- W2560750372 workType "article" @default.